

KING PHARMACEUTICALS INC

Form 8-K

July 29, 2003

Table of Contents

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 29, 2003

King Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Tennessee
(State or other jurisdiction
of incorporation)

0 24425
(Commission
File Number)

54-1684963
(IRS Employer
Identification Number)

501 Fifth Street, Bristol, Tennessee
(Address of principal executive offices)

37620
(Zip Code)

Registrant's telephone number, including area code: **423-989-8000**

Not Applicable
(Former name or former address, if changed since last report)

TABLE OF CONTENTS

SIGNATURE

Exhibit Index

Ex-99.1 Press Release

Table of Contents

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits

None.
(c) Exhibits.

The following exhibits are filed pursuant to Item 601 of Regulation S-K:

Exhibits:

Exhibit Number	Description of Exhibit
99.1	Press Release of King Pharmaceuticals, Inc. dated July 29, 2003.

Item 9. Regulation FD Disclosure

On July 29, 2003, King Pharmaceuticals, Inc., a Tennessee corporation, issued a press release which announced its second quarter 2003 financial results.

In accordance with the Securities and Exchange Commission Release No. 34-47583 and the General Instructions B.2. and B.6. of Form 8-K, the information contained in this report, which is intended to be furnished under Item 12, Results of Operations and Financial Condition, is instead being furnished under Item 9, Regulation FD Disclosure. This information shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 29, 2003

KING PHARMACEUTICALS, INC.

By: /s/ James R. Lattanzi

James R. Lattanzi
Chief Financial Officer

Table of Contents

Exhibit Index

<u>Exhibit Number</u>	<u>Description of Exhibit</u>
99.1	Press Release of King Pharmaceuticals, Inc. dated July 29, 2003.